A Phase 3, randomized, blinded study comparing CPI-0610 and ruxolitinib with placebo and
ruxolitinib in myelofibrosis (MF) patients that have not been exposed previously to Janus
kinase inhibitors (JAKi). CPI-0610 is a small molecule inhibitor of bromodomain and
extra-terminal (BET) proteins. Evidence suggests that inhibition of both BET and JAK pathways
can result in synergistic reduction of disease and overall improvement in the prognosis of
MF.